Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir and what is the scope of freedom to operate?
Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir has six hundred and twenty-one patent family members in fifty-four countries.
Summary for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
International Patents: | 621 |
US Patents: | 17 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
US Patents and Regulatory Information for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Expired US Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2014530874 | HCVの治療に使用するためのDAAの(例えばABT−072もしくはABT−333との)併用治療 | ⤷ Sign Up |
Slovenia | 2340029 | ⤷ Sign Up | |
Cyprus | 1116060 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2011156578 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2203431 | 92666 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
2340029 | 1590012-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119 |
2203431 | C02203431/01 | Switzerland | ⤷ Sign Up | BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST. |
2203431 | 122015000040 | Germany | ⤷ Sign Up | PRODUCT NAME: DASABUVIR; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |